58915-18-7

Usage

Uses

Used in Pharmaceutical Research:
2-(2-Chloro-acetylamino)-benzoic acid methyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to be incorporated into the molecular structures of potential new drugs. Its presence in these compounds can contribute to their biological activity and therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(2-Chloro-acetylamino)-benzoic acid methyl ester serves as a versatile building block, enabling the creation of a wide range of chemical entities. Its reactivity and functional groups allow for various chemical reactions, facilitating the development of complex organic molecules for different applications.
Used in Drug Development:
2-(2-Chloro-acetylamino)-benzoic acid methyl ester is utilized in drug development as a precursor to biologically active molecules. Its incorporation into drug candidates can enhance their pharmacological properties, such as potency, selectivity, and bioavailability, making it a valuable component in the design and synthesis of novel therapeutic agents.
Used in Chemical Intermediates Industry:
As a chemical intermediate, 2-(2-Chloro-acetylamino)-benzoic acid methyl ester is employed in the production of other chemical compounds that may have applications in various industries, including pharmaceuticals, agrochemicals, and materials science. Its role in these processes is crucial for the synthesis of end products with desired properties and functions.

Upstream product

• 79-04-9 chloroacetyl chloride 
• 134-20-3 2-carbomethoxyaniline 
• 118-92-3 anthranilic acid 

Downstream Products

• 58915-10-9 2-(2-benzothiazol-2-ylsulfanyl-acetylamino)-benzoic acid methyl ester 
• 64893-00-1 2-[(N-tert-butyl-glycyl)-amino]-benzoic acid methyl ester 
• 58915-07-4 2-(2-benzooxazol-2-ylsulfanyl-acetylamino)-benzoic acid methyl ester 
• 3817-05-8 2-(chloromethyl)quinazolin-4(3H)-one 
• 5973-37-5 Methyl-N-iodacetylanthranilat 
• 96660-30-9 2-[2-(triphenyl-λ⁵-phosphanylidene)-acetylamino]-benzoic acid methyl ester 
• 64893-06-7 2-(3-tert-butyl-2-oxo-2λ⁴-[1,2,3]oxathiazolidin-5-ylideneamino)-benzoic acid methyl ester 
• 69764-13-2 2-({[(3,4-dichlorophenyl)oxy]acetyl}amino)benzoic acid 
• 713499-01-5 2-[2-(4-iodo-phenoxy)-ethanoylamino]-benzoic acid methyl ester 
• 906004-76-0 methyl 2-({[4-(1,2,4-benzotriazin-3-yl)-1-piperazinyl]acetyl}amino)benzoate 
• 1252046-50-6 methyl 2-{2-[1-(4-hydroxyphenyl)-1H-tetrazol-5-ylthio]acetamido}benzoate 
• 1295537-03-9 2-(5,6-dimethoxy-1H-benzo[d]imidazole-2-carboxamido)benzoic acid 
• 1295537-08-4 methyl 2-(5,6-dimethoxy-1H-benzo[d]imidazole-2-carboxamido)benzoate 
• 1428962-02-0 methyl 2-(2-((2-hydroxy-3-(1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)propyl)(methyl)amino)acetamido)benzoate 

Relevant academic research and scientific papers

O-amino aromatic amide derivative as well as preparation method and application thereof

The invention discloses an o-amino aromatic amide derivative as well as a preparation method and application thereof. The o-amino aromatic amide derivative is a compound with a structural general formula I, II and III or a pharmaceutically acceptable salt

Triazole sulfonamides derivatives and their use in agriculture

The invention provides a novel triazole sulfonamide derivative and application thereof in agriculture. , The invention relates to a triazole sulfonamides derivative as shown in a formula (I) and a preparation method thereof. I In formula (R)1 And R2 Are each independently hydrogen. C1 -6 Alkyl and the like, R3 Document C3 -8 Cycloalkyl, R4 -SO2 - NRa Rb , SO2 - C1 -6 Alkyl group, SO2 - C3 -8 Cycloalkyl, SO2 - C1 -3 Alkylene - C3 -8 Cycloalkyl, SO2 - Rc , C1 -3 Alkylene - C (＝ O) O-C1 -6 Alkyl or - C1 -3 Alkylene - C (＝ O) - NRd Re , Ra , Rb , Rc , Rd And Re Having the meaning of the invention. The compound, the composition containing the compound and/or the preparation provided by the invention has good bactericidal activity and can be used as a bactericide in agriculture.

Antidiabetic compounds

Compounds for the treatment of hyperglycemia and/or diabetes are provided. The compounds, which inhibit the enzyme dipeptidyl peptidase (DPP-4), are based on the structure where X may be present or absent an may be OH, Ar is an aryl group; and n ranges from 0 to 5.

2-substituted thioacetamide compound, and preparation method and application thereof

The invention discloses a 2-substituted thioacetamide compound, and a preparation method and an application thereof. The structure of the 2-substituted thioacetamide compound is represented by formulaI, and R in the formula I is a C1-C3 alkoxy group, halogen or NR1R2, wherein R1 and R2 are H and a C1-C3 alkyl group independently. The compound can effectively inhibit protein-arginine methyltransferase 5, and can be used as a PRMT5 inhibitor.

Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors

Protein arginine methyltransferase 5 (PRMT5) is an epigenetics related enzyme that has been validated as a promising therapeutic target for human cancer. Up to now, two small molecule PRMT5 inhibitors has been put into phase I clinical trial. In the prese

Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommended components of preferred combination antiretroviral therapies used for the treatment of human immunodeficiency virus (HIV) infection. These regimens are extremely effective in suppressing virus replication. Recently, our research group identified some N1-aryl-2-arylthioacetamido-benzimidazoles as a novel class of NNRTIs. In this research work we report the design, the synthesis and the structure–activity relationship studies of new compounds (20–34) in which some structural modifications have been introduced in order to investigate their effects on reverse transcriptase (RT) inhibition and to better define the features needed to increase the antiviral activity. Most of the new compounds proved to be highly effective in inhibiting both RT enzyme at nanomolar concentrations and HIV-1 replication in MT4 cells with minimal cytotoxicity. Among them, the most promising N1-aryl-2-arylthioacetamido-benzimidazoles and N1-aryl-2-aryloxyacetamido-benzimidazoles were also tested toward a panel of single- and double-mutants strain responsible for resistance to NNRTIs, showing in vitro antiviral activity toward single mutants L100I, K103N, Y181C, Y188L and E138K. The best results were observed for derivatives 29 and 33 active also against the double mutants F227L and V106A. Computational approaches were applied in order to rationalize the potency of the new synthesized inhibitors.

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.

1,3-dimethyl-7-substituted-quinazolinyl-2,4-diones, and synthesis method and application thereof

The invention discloses 1,3-dimethyl-7-substituted-quinazolinyl-2,4-diones. The structural general formula of the compounds is disclosed in the specification, wherein R1 is hydrogen or ethyl; and R2 is a benzene ring, benzene ring derivative, heterocyclic ring or aliphatic hydrocarbon. Part of compounds have favorable inhibiting activities for Candida albicans, Aspergillus flavus, Torula histolytica and Aspergillus fumigatus. The compounds have obvious inhibiting activities for chitin synthetase, have favorable antibacterial effects, and can be used for preparing drugs for anti-pathogenic microorganisms.

Chloroquinoline-acetamide hybrids: A promising series of potential antiprotozoal agents

In an endeavour to develop efficacious antiprotozoal agents 2-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]acetamide derivatives were synthesized and screened in vitro against the HM1:IMSS strain of E. histolytica and 3D7 strain of P. falciparum. Among the twenty-seven synthesized compounds, eleven evinced propitious anti-amoebic activity with IC50 values ranging from 0.41 to 1.80 μM) lower than the standard drug metronidazole (IC50 1.80 μM). All the compounds inhibited the in vitro growth of P. falciparum (IC50 range: 0.30-33.52 μM). Compounds A22 and A25 were found to be the most active antimalarial derivatives, and compound A16 the most active in inhibiting β-haematin formation; however compound A25 displayed the more favourable safety profile. The crystal structure for the compounds A7, A8, A12 and A21 was also determined. The molecular docking of crystal resolved inhibitors with PfDHFR allowed identification of stabilizing interactions within enzyme active sites. These compounds affirm the potential for further derivatives to enhance antiprotozoal activity whilst retaining their safety profile.

Design, synthesis and evaluation of novel quinazoline-2,4-dione derivatives as chitin synthase inhibitors and antifungal agents

A series of novel 1-methyl-3-substituted quinazoline-2,4-dione derivatives were designed, synthesized, and characterized by 1H NMR, 13C NMR and MS spectral data. Their inhibition against chitin synthase (CHS) and antifungal activities were evaluated in vitro. Results showed compounds 5b, 5c, 5e, 5f, 5j, 5k, 5l, and 5o had strong inhibitory potency against CHS. Compound 5c, which has the highest potency among these compounds, had a half-inhibition concentration (IC50) of 0.08 mmol/L, while polyoxin B as positive drug had IC50 of 0.18 mmol/L. These IC 50 values of compounds 5i, 5m, 5n, and 5s were greater than 0.75 mmol/L, which revealed that those compounds had weak inhibition activity against CHS. Moreover, most of these compounds exhibited moderate to excellent antifungal activities. In detail, to Candida albicans, the activities of compound 5g and 5k were 8-fold stronger than that of fluconazole and 4-fold stronger than that of polyoxin B; to Aspergillus flavus, the activities of 5g, 5l and 5o were16-fold stronger than that of fluconazole and 8-fold stronger than that of polyoxin B; to Cryptococcus neoformans, the minimum-inhibition- concentration (MIC) values of compounds 5c, 5d, 5e and 5l were comparable to those of fluconazole and polyoxin B. The antifungal activities of these compounds were positively correlated to their IC50 values against CHS. Furthermore, these compounds had negligible actions to bacteria. Therefore, these compounds were promising selective antifungal agents.